Evidence map›Paper›PMID 42433260›Full record

ArticleACS nano medicine2026

A Dual-Pronged Hafnia-Prodrug-Lipid Nanoplatform Coupling Radiosensitization and DNA Homologous Recombination Inhibition.

David Skrodzki, Pranay Saha, Matthew Molinaro, Nada Maher, Shraddha Krishnakumar, Nivetha Gunaseelan, Mecit Altan Alioglu, Oguzhan Colak, Gabriela Cepeda, Parikshit Moitra and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS nano medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

David SkrodzkiDepartment of Materials Science and Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802, United States.ORCID https://orcid.org/0000-0003-2838-6446
Pranay SahaDepartment of Nuclear Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802, United States.ORCID https://orcid.org/0000-0003-3915-8182
Matthew MolinaroDepartment of Engineering Science and Mechanics, The Pennsylvania State University, University Park, Pennsylvania 16802, United States.ORCID https://orcid.org/0000-0002-6113-4358
Nada MaherDepartment of Nuclear Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802, United States.
Shraddha KrishnakumarDepartment of Biomedical Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802, United States.
Nivetha GunaseelanDepartment of Biomedical Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802, United States.ORCID https://orcid.org/0000-0003-4939-1658
Mecit Altan AliogluDepartment of Nuclear Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802, United States.
Oguzhan ColakDepartment of Nuclear Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802, United States.
Gabriela CepedaDepartment of Biomedical Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802, United States.
Parikshit MoitraDepartment of Nuclear Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802, United States.ORCID https://orcid.org/0000-0002-7679-7859
Timothy M FanDepartment of Veterinary Clinical Medicine, University of Illinois Urbana-Champaign, Urbana, Illinois 61802, United States.
Dipanjan PanDepartment of Materials Science and Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802, United States.ORCID https://orcid.org/0000-0003-0175-4704

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging nanomedicine strategies have established clinical translation and the ability to offset conventional therapeutic challenges. This study aimed to report the development and analysis of a nanoscale material that functioned as both a high-Z radiosensitizer and a prodrug delivery system. In this study, a nanoscale platform using two complementary radiosensitizing mechanisms was designed and developed to overcome nonspecific toxicity, which is a challenge in both chemotherapy and radiotherapy. High-Z physical radiosensitization was coupled with the inhibition of a critical DNA double-strand break repair mechanism, homologous recombination, through a lipid nanoparticle decorated with ultrasmall Hafnia nanoparticles and loaded with an amphiphilic prodrug. In vitro and in vivo studies demonstrated significant enhancement of therapeutic effects, cell killing, or tumor regression, respectively, versus radiation alone. These results support the use of this combination system as a practical strategy for maintaining treatment efficacy at modest doses of radiation and offset associated adverse effects.

Indexed as

CancerChemotherapyCombinatorial nanoscale strategiesHigh-Z radiosensitizationProdrugsRadiotherapy

Identifiers

PMID42433260
PMCPMC13352939

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.